MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 226 filers reported holding MYRIAD GENETICS INC in Q4 2016. The put-call ratio across all filers is 9.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $189,000 | -75.1% | 13,185 | -52.7% | 0.01% | -68.3% |
Q4 2019 | $758,000 | -42.4% | 27,854 | -39.4% | 0.04% | -35.9% |
Q3 2019 | $1,315,000 | -4.8% | 45,929 | -7.7% | 0.06% | -3.0% |
Q2 2019 | $1,382,000 | -16.3% | 49,743 | -0.0% | 0.07% | -16.5% |
Q1 2019 | $1,652,000 | +14.7% | 49,746 | +0.4% | 0.08% | +3.9% |
Q4 2018 | $1,440,000 | -36.0% | 49,526 | +1.2% | 0.08% | -20.0% |
Q3 2018 | $2,250,000 | +22.7% | 48,921 | -0.3% | 0.10% | +11.8% |
Q2 2018 | $1,833,000 | +26.3% | 49,046 | -0.1% | 0.08% | +19.7% |
Q1 2018 | $1,451,000 | -13.9% | 49,099 | 0.0% | 0.07% | -9.0% |
Q4 2017 | $1,686,000 | -13.0% | 49,099 | -8.4% | 0.08% | -22.8% |
Q3 2017 | $1,939,000 | +40.9% | 53,599 | +0.7% | 0.10% | +34.7% |
Q2 2017 | $1,376,000 | +32.2% | 53,249 | -1.8% | 0.08% | +33.9% |
Q1 2017 | $1,041,000 | +3.9% | 54,224 | -9.8% | 0.06% | +1.8% |
Q4 2016 | $1,002,000 | -53.7% | 60,084 | -42.8% | 0.06% | -54.5% |
Q3 2016 | $2,162,000 | -48.4% | 105,071 | -23.3% | 0.12% | -51.0% |
Q2 2016 | $4,193,000 | – | 137,012 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |